GLP-1 medications have become one of the most discussed developments in metabolic medicine, and with the attention has come a lot of noise. This article does something narrower and more useful than the hype: it explains what this class of medication actually does in the body, in plain terms, and why that mechanism is relevant to the specific metabolic shifts of perimenopause. Understanding the mechanism is what lets you evaluate — with a provider — whether it's a reasonable fit, rather than reacting to headlines.

A note before we start: this is educational information about how a class of medication works. It is not medical advice, not a recommendation, and not a claim about results. Whether any medication is appropriate for a specific person is a decision only a licensed provider can make after reviewing that person's full history.

What GLP-1 actually is

GLP-1 — glucagon-like peptide-1 — isn't a drug to begin with. It's a hormone your own body already makes. It's released by cells in your intestine in response to food, and it plays a natural role in regulating blood sugar and appetite. [1] The catch is that natural GLP-1 breaks down within minutes, cleared by an enzyme almost as fast as it's released. [2]

GLP-1 receptor agonists — the medication class that includes semaglutide — are engineered versions of this signal that resist that rapid breakdown, so the effect lasts far longer than the body's own short-lived pulse. [2] (Tirzepatide works on the same GLP-1 pathway but is technically a dual agonist, acting on a second related receptor, GIP, as well. [3]) In plain terms: they mimic a hormone you already produce, but in a form that sticks around long enough to matter.

The mechanism, in four parts

Research describes GLP-1 receptor agonists as working through several complementary pathways rather than a single lever: [3]

  • They act on appetite centers in the brain. GLP-1 receptors sit on neurons in brain regions that govern hunger and fullness. Activating them increases satiety and reduces appetite — the sense of being satisfied with less. [1][3]
  • They slow gastric emptying. Food leaves the stomach more slowly, which prolongs the feeling of fullness after a meal. [1][3]
  • They enhance insulin secretion — but glucose-dependently. They prompt the pancreas to release insulin in response to rising blood sugar, which is why they improve glycemic control primarily when it's needed rather than indiscriminately. [1][3]
  • They reduce glucagon, the hormone that raises blood sugar, further supporting glucose regulation. [3]

The appetite and satiety effects are described in the research as arising from the combined action in the gut and the brain — central and peripheral receptors working together — not from any one of these alone. [4]

Why the mechanism is relevant in perimenopause

Here's the connection that makes this class worth understanding specifically in midlife. The metabolic shifts of perimenopause — covered in our companion articles — center on two things: a drift toward insulin resistance as estrogen declines, and changes in appetite regulation and fat storage. GLP-1's mechanism happens to intersect both of those domains: glucose regulation and appetite signaling.

That intersection is why the class is discussed in the context of midlife metabolic change — not because it's menopause-specific (it isn't), and not because it's a hormone therapy (it isn't that either). It's a metabolic medication whose mechanism touches the same systems perimenopause disrupts. Whether that intersection translates into an appropriate treatment for any individual is exactly the kind of question that requires a provider's judgment, not an article's.

The honest caveats

Three things worth stating plainly, because responsible information includes them.

First, this class of medication has real side effects. Because it slows gastric emptying, gastrointestinal effects — nausea, and others — are the most common, and they often occur around dose changes. [1] Any real medical conversation about GLP-1 includes its risks, not just its mechanism.

Second — and this is important for anyone researching compounded options specifically — compounded semaglutide and tirzepatide are not FDA-approved. While the branded versions of these molecules are FDA-approved for their specific indications, compounded medications are prepared by pharmacies, are not the same as the branded products, and have not undergone the same FDA review for safety and efficacy. This is a real distinction, not a technicality, and it belongs in any honest discussion of these medications.

Third, mechanism is not a promise. Understanding how a medication works in the body is different from predicting what it will do for a specific person — that depends on individual physiology, health history, and much else, which is precisely why the medical-review step exists.

Where care fits

If understanding the mechanism has you wondering whether this class is a reasonable fit for your situation, the right next step isn't a purchase — it's an evaluation. A licensed provider reviews your history, your labs, and your goals, discusses the real risks and benefits, and determines whether treatment is appropriate for you.

That's the model Cypress is built around: care designed for the perimenopausal body, with a licensed provider reviewing you first. If you want to understand what that review involves, you can learn how provider-reviewed care works.